Stiff P J
Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois, USA.
Oncology (Williston Park). 1998 Oct;12(10 Suppl 8):56-62.
It was not until 1995 that a phase III randomized trial demonstrated that autologous stem cell transplants (ASCT) improve the progression-free and overall survival of patients with relapsed refractory diffuse aggressive non-Hodgkin's lymphoma. Investigators are now focusing on improving the clinical benefit of transplants. The relative contributions made by more intensive preparative regimens, purging, concomitant immunotherapy, and the timing of transplants are under study. Also, as transplant trials shift from relapsed disease to initial therapy, anticipated benefits must be balanced against both short-term and long-term toxicities.
直到1995年，一项III期随机试验才证明自体干细胞移植（ASCT）可改善复发难治性弥漫性侵袭性非霍奇金淋巴瘤患者的无进展生存期和总生存期。研究人员目前正专注于提高移植的临床益处。更强化的预处理方案、净化、联合免疫疗法以及移植时机所起的相对作用正在研究之中。此外，随着移植试验从复发性疾病转向初始治疗，预期益处必须与短期和长期毒性相权衡。
